Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 10/20 | 0.64 |
| ▸ | CYP11B1 | P15538 | 8/20 | 0.64 |
| ▸ | G6PD | P11413 | 1/20 | 0.62 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.52 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.50 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.50 |
| ▸ | RAD51 | Q06609 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | DHFR | P00374 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.45 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2215667 | 0.90 | CYP11B2 (0.60) | CYP11B2CYP11B1G6PDAOC3CYP17A1 | |
| SCHEMBL2326240 | 0.86 | ALDH1A1 (0.52) | CYP11B2CYP11B1G6PDAOC3CYP19A1 | |
| SCHEMBL1104863 | 0.85 | AOC3 (0.56) | CYP11B2CYP11B1G6PDAOC3MAPT | |
| SCHEMBL2330188 | 0.84 | HDAC1 (0.49) | CYP11B2CYP11B1G6PDMAPTNPC1 | |
| SCHEMBL4589453 | 0.84 | ALDH1A1 (0.57) | CYP11B2CYP11B1G6PDMAPTNPC1 | |
| SCHEMBL2326385 | 0.83 | ALDH1A1 (0.59) | CYP11B2CYP11B1G6PDMAPTRAB9A | |
| SCHEMBL2330609 | 0.83 | ALDH1A1 (0.59) | MAPTNPC1RAB9ADHFRALDH1A1 | |
| SCHEMBL2211752 | 0.81 | MAPT (0.61) | CYP11B2CYP11B1G6PDAOC3CYP19A1 | |
| SCHEMBL2819720 | 0.81 | G6PD (0.48) | CYP11B2CYP11B1G6PDAOC3MAPT | |
| SCHEMBL2325922 | 0.81 | NPC1 (0.49) | NPC1RAB9AALDH1A1HPGDMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1474415-B1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | BAYER SCHERING PHARMA AG (DE) | 2011-07-27 | — | — | EP | disclosed |
| US-7683081-B2 | 1-phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2010-03-23 | — | — | US | disclosed |
| US-20050267160-A1 | 1-Phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-12-01 | — | — | US | disclosed |
| US-6962932-B2 | 1-phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2005-11-08 | — | — | US | disclosed |
| EP-1474415-A1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | Schering Aktiengesellschaft (DE) | 2004-11-10 | — | — | EP | disclosed |
| US-20030229085-A1 | 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-12-11 | — | — | US | disclosed |
| WO-2003068766-A1 | 1-PHENYL-2-HETEROARYL-SUBSTITUTED BENZIMIDAZOLE DERIVATIVES, THE USE THEREOF FOR PRODUCING DRUGS USED IN THE TREATMENT OF IMMUNOLOGICAL DISEASES | SCHERING AKTIENGESELLSCHAFT (DE) | 2003-08-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050267160-A1 | 1-Phenyl-2-heteroaryl-substituted benzimidazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | CD4, NFATC1, ICOS | CYP11B2 512/4885CYP11B1 918/4885G6PD 1355/4885 |
| US-20030229085-A1 | 1-Phenyl-2-heteroaryl-substituted benzimdazole derivatives, their use for the production of pharmaceutical agents as well as pharmaceutical preparations that contain these derivatives | CD4, ICOS, NFATC1 | CYP11B2 349/4885CYP11B1 595/4885G6PD 1144/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.